Cell Therapeutics, Inc. (CTI) (Nasdaq: CTICD)’s XYOTAX™ is a novel biologically- enhanced version of one of the most used cancer drugs -Taxol®.
Recently, XYOTAX® has been assigned a Fast Track Designation by the USFDA for the treatment of PS2 (poor performance status) women with first-line advanced non-small cell lung cancer (NSCLC), following the company’s submission of a Special Protocol Assessment (SPA) for the design of its phase III trial of XYOTAX for women with advanced NSCLC.
The said trial (PGT306) is expected to enrol 300 poor performance status (PS2) women who have advanced stage non- small cell lung cancer (NSCLC) and have not received prior chemotherapy, and will focus exclusively on women with normal estrogen levels.
Find more details from the press release.
[Photo Credit: Office of IP Development and Commercialization, FSU]
.jpg)
Comment Preview